Caly et al. 1 reported that ivermectin inhibited severe acute respiratory syndrome‐
coronavirus 2 (SARS‐CoV‐2) in vitro for up to 48 hours using ivermectin at 5 μM. The …

Background: Up-to-date, there is no recognized effective treatment or vaccine for the
treatment of COVID-19 that emphasize urgency around distinctive effective therapies. This …

In the past decade, dried blood spot (DBS) sampling has been used increasingly for
microsampling in various fields. This is predominantly driven by the significant advantages …

Malaria is one of the most life-threatening infectious diseases and constitutes a major health
problem, especially in Africa. Although artemisinin combination therapies remain efficacious …

High concentrations of ivermectin demonstrated antiviral activity against SARS-CoV-2 in
vitro. The aim of this study was to assess the safety and efficacy of high-dose ivermectin in …

Hundreds of researchers are working to develop a vaccine and are evaluating drugs to
mitigate the adverse health and economic consequences of COVID-19 (Coronavirus …

Background Ivermectin, an effective treatment for scabies, is not licensed for children
weighing< 15 kg. Pharmacokinetic modelling has shown a 3 mg dose in young children (2 …

Abstract Background Ivermectin (22, 23-dihydroavermectin B1a: H2B1a) is an endectocide
used to treat worm infections and ectoparasites including lice and scabies mites …

Patients receiving immunosuppressant therapy, require intensive follow-up via therapeutic
drug monitoring (TDM). This puts quite a burden on the patient involving frequent hospital …

This review provides an overview on the current applications of dried blood spots (DBS) as
matrices for therapeutic drug (TDM) and drug or disease response monitoring (DRM) …